

# Information for Colorado Prescribers of Prescription Drugs Provided Pursuant to Colorado House Bill 19-1131

## **Ocrevus Zunovo™** (ocrelizumab-hyaluronidase-ocsq)

<b><u>Marketed Drug</u></b>	<b><u>WAC Unit Price*</u></b>	<b><u>WAC Package Price*</u></b>
Ocrevus Zunovo 920 mg - 23,000 unit/23 mL Vial	\$ 1,794.86608 per mL	\$ 41,281.92 per vial

### **Generic Drugs in Same Therapeutic Class\*\*** N/A

**\*Wholesale Acquisition Cost (WAC)** as published by FDB represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to FDB by the manufacturer. WAC does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price. FDB does not perform any independent investigation or analysis of actual transaction prices for purposes of reporting WAC. FDB relies on manufacturers to report or otherwise make available the values for the WAC.

For more information about First Databank's drug pricing policy, visit  
<https://www.fdbhealth.com/drug-pricing-policy>

**\*\*Generics included (if any)** are in the same or similar therapeutic class of the listed Genentech product(s) meaning they have the same or similar mechanism of action of the listed Genentech product(s), and are approved to treat at least one approved indication of the listed Genentech product(s). Refer to the relevant prescribing information for each listed product.

Source: AnalySource® 01/02/2025 as reprinted with permission by First Databank, Inc. All rights reserved. ©2025

M-US-00025436(v2.0)